

# Anti-ErbB3 [RTJ1]

**Catalogue number:** 151157

**Sub-type:** Primary antibody

**Images:**

## Contributor

**Inventor:** Bill Gullick

**Institute:** Imperial Cancer Research Fund

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-ErbB3 [RTJ1]

**Alternate name:**

**Class:** Monoclonal

**Conjugate:** Unconjugated

**Description:** Monoclonal antibody directed against ErbB3 kinase, widely prevalent in GI and breast tumours.

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:** IgM

**Reactivity:** Human

**Selectivity:**

**Host:** Mouse

**Immunogen:** Synthetic Peptide from C terminus of human c-erbB3

**Immunogen UNIPROT ID:** P21860

**Sequence:**

**Growth properties:**

**Production details:**

**Formulation:**

**Recommended controls:**

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:**

## Target details

**Target:** ErbB3 (Her3)

**Target alternate names:**

**Target background:** The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB3 is normally found in non-dividing differentiated epithelial cells, neurones and hepatocytes. ErbB3 was found to be kinase impaired, having only 1/1000 the autophosphorylation activity of EGFR and no ability to phosphorylate other proteins. Therefore, ErbB3 must act as an allosteric activator. The kinase-impaired ErbB3 is known to form active heterodimers with other members of the ErbB family, most notably the ligand binding-impaired ErbB2. It has approximately 80% prevalence in a wide variety of tumours of the gastro-intestinal tract, and approximately 20% prevalence in breast cancer. This antibody is specific against c-erbB-3 oncoprotein that is expressed in a variety of human normal, foetal and neoplastic epithelial tissues.

**Molecular weight:** 105 kDa

**Ic50:**

## Applications

**Application:** IHC ; IP ; WB

**Application notes:**

## Handling

**Format:** Liquid

**Concentration:** 1 mg/ml

**Passage number:**

**Growth medium:**

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:** PBS with 0.02% azide

**Storage conditions:** Store at -20° C frozen. Avoid repeated freeze / thaw cycles

**Shipping conditions:** Shipping at 4° C

## Related tools

## Related tools:

## References

**References:** Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. ; Ragazzon et al. 2014. Eur J Endocrinol. 2014 Feb 4;170(3):385-91. PMID: 24347427 ; Bandyopadhyay et al. 2007. Aging Cell. 6(4):577-91. PMID: 17578512. ; Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. ; Lee et al. 2007. Clin Cancer Res. 13(3):832-8. PMID: 17289874. ; Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. ; Bartkova et al. 2003. J Pathol. 200(2):149-56. PMID: 12754735. ; Deregulation of the RB pathway in human testicular germ cell tumours. ; Brtek et al. 1992. Oncogene. 7(1):101-8. PMID: 1741157. ; Cellular localization and T antigen binding of the retinoblastoma protein. ; Grand et al. 1989. Oncogene. 4(11):1291-8. PMID: 2682458. ; The expression of the retinoblastoma gene product Rb1 in primary and adenovirus-transformed human cells.

CancerTools.org